Check Before You Invest : Concord Biotech Ltd

Q: Which industry/sub-sector does Concord Biotech Ltd belong to?

Concord Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Concord Biotech Ltd a good quality company?

Concord Biotech Ltd is a good quality company, based on a consistently good multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Concord Biotech Ltd undervalued or overvalued?

Concord Biotech Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 37.63, Historic Median: 51.41. Price to Book, Current: 6.22, Historic Median: 9.65. Price to Sales, Current: 10.15, Historic Median: 14.76. EV to EBITDA, Current: 24.17, Historic Median: 32.35

Q: Is Concord Biotech Ltd a good buy now?

Concord Biotech Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Concord Biotech Ltd?

Concord Biotech Ltd revenue growth is 18% for FY-2025, which is in line with its 5-year CAGR of 18.56%, indicating stable growth.

Q: Gross Profit margin of Concord Biotech Ltd?

Concord Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 45.9% for FY-2025, which is in line with its 5-year median of 45.5%, indicating stable margins.

Q: Operating Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 42.25% for FY-2025, which is in line with its 5-year median of 42.25% indicating stable margins.

Q: Net Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Net Profit Margin is 30.97% for FY-2025, is in line with its 5-year median of 30.3%, indicating stable margins. Profitability Metrics. Gross Profit Margin (%), Current: 45.9, Historic Median: 45.5. Operating Profit Margin (%), Current: 42.25, Historic Median: 42.25. Net Profit Margin (%), Current: 30.97, Historic Median: 30.3

Q: Return on Asset of Concord Biotech Ltd?

Concord Biotech Ltd Return on Asset is 19.9%, which is in line with its 5-year historical median of 19.17%, indicating stable asset utilization efficiency.

Q: Return on capital employed (ROCE) of Concord Biotech Ltd?

Concord Biotech Ltd Return on capital employed is 29.62% for FY-2025, which is in line with its 5-year historical median of 29.13%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Check Before You Invest : Concord Biotech Ltd

Snapshot

Q.1 Which industry/sub-sector does Concord Biotech Ltd belong to?

Concord Biotech Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Concord Biotech Ltd a good quality company?

Concord Biotech Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Concord Biotech Ltd undervalued or overvalued?

Concord Biotech Ltd appears Somewhat Undervalued, as its key valuation ratios are lower than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	37.63	51.41
Price to Book	6.22	9.65
Price to Sales	10.15	14.76
EV to EBITDA	24.17	32.35

Q.4 Is Concord Biotech Ltd a good buy now?

Concord Biotech Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Concord Biotech Ltd?

Concord Biotech Ltd revenue growth is 18% for FY-2025, which is in line with its 5-year CAGR of 18.56%, indicating stable growth.

Q.2 Gross Profit margin of Concord Biotech Ltd?

Concord Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is 45.9% for FY-2025, which is in line with its 5-year median of 45.5%, indicating stable margins.

Q.3 Operating Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 42.25% for FY-2025, which is in line with its 5-year median of 42.25% indicating stable margins.

Q.4 Net Profit Margin of Concord Biotech Ltd?

Concord Biotech Ltd Net Profit Margin is 30.97% for FY-2025, is in line with its 5-year median of 30.3%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	45.9	45.5
Operating Profit Margin (%)	42.25	42.25
Net Profit Margin (%)	30.97	30.3

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Concord Biotech Ltd?

Concord Biotech Ltd Return on Asset is 19.9%, which is in line with its 5-year historical median of 19.17%, indicating stable asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Concord Biotech Ltd?

Concord Biotech Ltd Return on capital employed is 29.62% for FY-2025, which is in line with its 5-year historical median of 29.13%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 13.5%, indicating value creation.

Q.7 Return on Equity (ROE) of Concord Biotech Ltd?

Concord Biotech Ltd Return on equity is 22.26% for FY-2025, which is in line with its 5-year historical median of 21.88%, indicating the business is making similar use of its shareholders capital.

Q.8 Cash conversion cycle of Concord Biotech Ltd?

Concord Biotech Ltd Cash conversion cycle is 146 days, above its 5-year historical median of 131 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	0.64	0.57
ROE (%)	22.26	21.88
ROCE (%)	29.62	29.13
Cash Conversion Cycle	146 days	131 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Concord Biotech Ltd?

Concord Biotech Ltd Debt-to-Equity ratio is 0.00, which is lower the industry average of 0.14, indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Concord Biotech Ltd?

Concord Biotech Ltd Debt to cash flow from operations is 0, which is at a healthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Concord Biotech Ltd?

Q.1 Promoter shareholding and pledge status of Concord Biotech Ltd?

Promoters hold 44.08% of the Concord Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Concord Biotech Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Concord Biotech Ltd vs industry peers?

Concord Biotech Ltd revenue CAGR is 18.56%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	18	5.4
Gross Profit Growth (%)	18.8	14
Operating Profit Growth (%)	17.4	11.5
Net Profit Growth (%)	20.8	12

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	0.64	0.79
ROE (%)	22.26	9.17
ROCE (%)	29.62	11.52
Cash Conversion Cycle (days)	145.81	76

Valuation & price assessment

Q.1 Stock return of Concord Biotech Ltd over the last decade?

Over the last 1 year(s), the stock has delivered a CAGR of -24.97% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	-	-	-25%

Q.2 Valuation ratios of Concord Biotech Ltd vs historical?

The current P/E ratio of 37.63 is lower than its historical median of 51.41, indicating that the stock is trading below its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	37.63	51.41	31.09
Price to Book	6.22	9.65	2.85
Price to Sales	10.15	14.76	2.82
EV to EBITDA	24.17	32.35	15.99

Check more companies

4. Wockhardt

7. Neuland Laboratories

8. Piramal Pharma

9. Astrazeneca Pharma

10. Granules India

Check trending companies

1. Ambuja Cements Ltd.

2. Bata India Ltd.

3. Krishna Institute of Medical Sciences Ltd

4. Gujarat State Fertilizers & Chemicals Ltd.

5. Aurobindo Pharma Ltd.

Check Before You Invest : Concord Biotech Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.